Data sharing initiative ATOM, of which GlaxoSmithKline is a member, wants to cut the time it takes to get from concept to molecule through comprehensive data sharing. John Baldoni, founder of ATOM and co-chair of its governing board, talks to Scrip about the consortium’s goals and bringing other big pharmas on board…

Don’t be deceived. John Baldoni may have 37 years’ experience in often conservative pharma. But he's not into incremental innovation…

The average time to identify a new cancer drug is six years. Since one of every four deaths in the U.S. is due to cancer, a lot of lives could be saved if that drug development time could be cut down to just a year…

When I explain my job to my 3-year-daughter, I say that I spend my time going to lots of meetings to listen to people’s ideas, or to ask them to listen to mine. I tell her that once we agree on an idea, it is my job to make it happen…to make it real…

This will give you hope that a treatment or cure is imminent - super computing is joining the search for a cure…

A new open, sharable platform that combines high-powered computing and data shared from public and industry sources is designed to accelerate the discovery of new cancer drugs…

The goal itself is jaw-dropping. Cut the development for cancer-fighting drugs — a notoriously lengthy and expensive process — from six years to one…

A global pharma company is teaming up with federal research labs and academics in an ambitious effort to slash the time spent screening potential cancer drugs before they make it into the clinic for testing…